The surveillance of patients with pancreatic cysts represents an important opportunity to prevent the progression of pre-invasive cysts to pancreatic cancer. Pancreatic cyst evaluation relies on pancreatic imaging but cannot adequately evaluate the neoplastic nature of pancreatic cysts. Pancreatic cyst fluid analysis has the potential to improve the evaluation of pancreatic cysts, better markers are needed. In this study, we evaluated the ability of cyst fluid telomerase activity to predict neoplastic grade of pancreatic cysts.
INTRODUCTION
The evaluation and management of patients with pancreatic cysts can be a significant clinical challenge (1) . A number of different pathologies with a wide spectrum of malignant potential can produce a cyst in the pancreas (1) . Most neoplastic pancreatic cysts are intraductal papillary mucinous neoplasms (IPMNs). Although the vast majority of IPMNs do not progress, some IPMNs do progress to invasive cancer (2) . Patients with good performance status suspected to have an IPMN with low-grade dysplasia (LGD) can be managed with surveillance while cysts with high-grade dysplasia (HGD) or an associated low-stage invasive cancer should be surgically resected (3, 4) . Serous cystic neoplasms (SCN) are virtually always benign, and some SCNs can be difficult to distinguish from IPMNs and other cysts with malignant potential (5) . Mucinous cystic neoplasms (MCNs) have significant malignant potential and are usually resected without any surveillance (3) .
Guidelines for the management of a patient with a pancreatic cyst currently are based on the patient's clinical symptoms and imaging findings. The most recent international consensus guidelines (ICG 2012) used clinical and imaging findings based on computed tomography (CT) or magnetic resonance imaging (MRI) to classify pancreatic cysts into those with "high-risk stigmata", "worrisome features", or "low-risk" (3) . These guidelines recommend surgical intervention for cases with "high-risk stigmata" while those with "worrisome features" should be further evaluated by endoscopic ultrasonography (EUS) (6) . These guidelines are effective, but still some patients who undergo pancreatic resection for a cyst with "worrisome features" (such as a history of pancreatitis, a cyst size of ≥30 mm, a thickened cyst wall, or a non-enhancing mural nodule) will have a lesion with little or no malignant potential (such as IPMNs with low-grade dysplasia or an SCN thought preoperatively to be mucinous neoplasm) (7, 8) . Indeed, recent evidence indicates that most patients with worrisome features who do not undergo pancreatic resection will not progress to death over the next 5 years (9). At the same time, once an invasive cancer arises progression may be rapid (10), and recurrence after resection and diminished survival is common even for patients with small cancers (11).
Cytological assessment of cystic tumors of the pancreas and carcinoembryonic antigen (CEA) measurements have clinical utility, but they are both imperfect (12, 13). The detection of somatic mutations and copy number alterations in cyst fluid samples using next-generation sequencing has shown promise as an approach to classify pancreatic cysts (14, 15) . Other pancreatic cyst fluid markers have been evaluated for their clinical utility, but to date none have been shown to reliably predict neoplastic grade (16) (17) (18) (19) (20) (21) . The development of additional cyst fluid markers that can predict the grade of neoplasia in a pancreatic cyst would have clinical utility. One marker that has been shown to indicate evidence of cancer in a variety of diagnostic settings is telomerase (22) .
Telomerase is not expressed in most normal somatic cells but is usually expressed during neoplastic development and plays an important role in the maintenance of telomere length and in the immortalization of neoplastic cells (23, 24) .
Telomerase activity can be measured directly using the telomerase repeat amplification protocol (TRAP) assay (25) (26) (27) (28) . In one study, telomerase activity, measured using gel-TRAP in fine needle biopsies from the walls of 19 pancreatic cystic neoplasms and 10 pancreatic pseudocysts, was reported to be useful in distinguishing malignant cysts from benign cysts and pseudocysts (29). An alternative to measuring telomerase activity is to measure the expression of one of its RNA components, TERT, whose expression closely correlates with telomerase activity and can be more readily assayed in clinical samples (30). TERT RNA levels in pancreatic juice samples collected from the pancreatic duct can accurately differentiate benign from malignant pancreatic lesions (31-33). Studies have also measured TERT RNA in resected pancreatic cystic neoplasm specimens as a marker of telomerase activity (34).
The original TRAP assay has been modified to incorporate real-time quantitative PCR (27, (35) (36) (37) (38) , and more recently, using digital-droplet PCR (ddPCR) to quantify telomerase activity more reliably and to avoid gel-based methods (39) . DdPCR involves isolating individual DNA molecules from a sample into nanoliter sized droplets by emulsification so that thousands of individual PCR reactions can occur (40) (41) (42) . Simple, precise, and reproducible quantification of the absolute amount of target DNA can be determined by counting the number of positive droplets after PCR.
In the present study, we evaluated the diagnostic accuracy of pancreatic cyst fluid telomerase measurements determined by ddPCR (dd-TRAP) as an approach to distinguishing pancreatic cysts with high-grade dysplasia and/or invasive cancer from those with benign features or lower grades of dysplasia.
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MATERIALS AND METHODS

Patients and specimens
Two hundred thirty-three patients (194 in a discovery set, 39 validation set) who had undergone surgical resection for a cystic pancreatic lesion at Johns Hopkins Hospital between 2008 to March 2016 and had pancreatic cyst fluid collected from their surgical resection specimen in the pathology laboratory as well as 36 subjects who had their pancreatic cyst fluid collected by fine needle aspiration during endoscopic ultrasound were studied. Ten cases in the discovery set and four cases in the validation set were excluded because their cyst fluid sample was inadequate for telomerase analysis (insufficient volume of sample available or degraded protein). Patient information including demographics, clinical symptoms, preoperative imaging findings, cyst fluid cytology and CEA values were obtained from hospital records. Pancreatic imaging findings were classified on the basis of pancreatic CT and/or MRI results into "high-risk stigmata", "worrisome features", and "low-risk" following the ICG 2012 algorithm (3). The diagnostic accuracy of cyst fluid CEA was evaluated using the cut-off of 192 ng/mL as previously described (43). The decision to operate was based on the clinical estimated risk of cancer, or for symptoms thought to be caused by the cyst.
Cases who underwent surgical resection who were classified as low-risk had a variety of indications for resection including suspected MCN, elevated cyst fluid CEA, significant increase in cyst diameter but not 3cm, symptoms suspected to be due to the cyst and 
Gel-TRAP assay
The telomerase repeat amplification protocol (TRAP) assay measures endogenous telomerase within cell extracts by the detection of added TTAGGG hexameric repeats catalyzed onto the 3' end of an oligo (the telomeric TS primer (26, 39) ). One μg of protein extract from cell pellets was applied and incubated with 50 μL Institutes of Health, Bethesda, MD, USA). Telomerase activity measured by the ratio of the intensity of 6-bp ladder to that of an internal control (IC) was calculated based on the following formula: ((intensity of sample's 6-bp ladder) -(background intensity between the sample lanes))/intensity of sample's IC band (27) .
Digital Droplet TRAP assay
For ddPCR, each 20 μL reaction mixture contained 1 × ddPCR EvaGreen Supermix (Bio-Rad, Hercules, CA, USA), 50 nM of TS and ACX primer, 2 μL of extension reaction mixture (the same as for the gel-TRAP assay described above). The 20 μL droplet ddPCR reaction mixture was then loaded into the DG8 disposable droplet generator cartridge (Bio-Rad), and placed into the QX200 Droplet Generator (Bio-Rad).
Following droplet generation, the water-in-oil droplet emulsions were transferred to a 96-well polypropylene PCR plate (twin.tec PCR plate; Eppendorf, Hauppauge, NY, USA). The plate was heat-sealed with foil using a PX1 PCR Plate Sealer (Bio-Rad) and placed in a Veriti Thermal Cycler (Applied Biosystems). PCR conditions were 95°C for 5 minutes (1 cycle), was followed by 37 cycles of 95°C for 30 sec, 54°C for 30 sec, 72°C for 30 sec. A dye-stabilization step was also included at the end of PCR (4°C for 5 min then, 95°C for 5 min, and finally at 12°C indefinite hold). The temperature ramp rate was set to 2.5°C/sec, and the lid was heated to 105°C, according to the manufacture's recommendations. After thermal cycling, droplet reading was performed on a QX200 ddPCR Droplet Reader (Bio-Rad). Analysis was done using QuantaSoft 
Statistics
The non-parametric Mann-Whitney U-test was used to compare continuous variables. The Fisher's exact test was used to compare categorical variables.
Correlations between two different variables were assessed by scatter-plot and R 2 value.
The diagnostic accuracy of telomerase activity for predicting the presence of either invasive cancer or high-grade dysplasia was assessed by receiver operating characteristics (ROC) curve analysis. The cut-off value was defined as the result with the highest sensitivity and specificity that lay closest to the left upper corner of the curve. Separate analyses were performed for discovery and validation samples followed by combined analysis. A multivariate analysis using the logistic regression model was performed including the variables with statistical significance by univariate analysis.
Statistical analysis was performed using GraphPad Prism V6.0 (GraphPad Software, San Diego, CA, USA) and JMP Pro 11.0.0 statistical software (SAS Institute Inc., Cary, NC, USA). P-value of less than 0.05 was considered to statistically significant.
RESULTS
Research.
on We next detected the dynamic range and limit of detection of the dd-TRAP assay and compared it to the conventional gel-TRAP assay using serial dilutions of MIAPaCa-2 cell extracts. The dd-TRAP assay had a greater dynamic range and lower limit of detection than the gel-TRAP assay. The gel-TRAP assay had a dynamic range from 8 ng to 500 ng (gel electrophoresis and densitometry, Supplementary Figures S3A and S3B), while the dd-TRAP could detect telomerase activity between 0.8 ng and 2,500 ng of MIAPaCa-2 protein extract ( Supplementary Figures S3C and S3D ). The limit of detection of the dd-TRAP assay was estimated to be ~9 telomerase-positive copies (Supplementary Figure S3E) and the dynamic range of the assay to be between 10 and 34,000 copies with high linearity (R 2 = 0.99657, Supplementary Figure S3F ).
We compared telomerase activity measured by gel-TRAP and dd-TRAP in 10
Research. pancreatic cancer cell lines and one immortalized pancreatic ductal epithelial cell (HPDE) with varying levels of telomerase activity (44), using levels in MIAPaCa-2 cell as a reference ( Figure 1A and 1B) . All cell lines including HPDE had telomerase activity as has been previously reported (45) (Figure 1B and 1C) . There was a close correlation between the telomerase activity measured by gel-TRAP and dd-TRAP (R 2 = 0.91498, Figure 1D ) with a wider detectable range again noted for the dd-TRAP assay.
Further description of the telomerase activity assay is provided in Supplemental Materials (and Suppl. Figures S4-6 ).
Pancreatic cystic fluid telomerase activity
We next evaluated the diagnostic performance of the dd-TRAP assay in pancreatic cyst fluid in 219 patients (Supplementary Table S1 ). First, 184 patients in the discovery set were studied; their cyst fluid characteristics, imaging findings, and final pathologies are provided in Supplementary Table S2 . Since the dd-TRAP assay measures enzymatic activity and therefore needs samples of optimal quality, we determined if cyst telomerase activity was affected by length of storage at -80°C or by the effects of freeze/thawing (some samples from each diagnostic group had previously undergone one or more freeze/thaws) (see Supplementary Results in Supplementary Materials). We found evidence that prior freeze/thawing, but not length of storage, was associated with reduced telomerase activity (Supplementary Figure S7) . Therefore, we stratified cyst fluid sample analyses according to their freeze/thaw status and analyzed the difference of telomerase activity across diagnostic groups. Table S3 ). We also measured telomerase activity in a validation set in surgically aspirated samples from 35 additional patients. In the validation set, telomerase activity had similarly high diagnostic performance; (AUC Among discovery set cases whose cyst fluid samples had undergone multiple (2 or 3) rounds of thawing and re-freezing, we found the differences in telomerase activity between the IPMN invasive cancer/HGD group vs. the IPMN IGD/LGD group were still statistically significant and had similar diagnostic accuracy to samples not previously thawed (Supplementary Figure S10) . Furthermore, the diagnostic performance of cyst fluid telomerase activity in the discovery set analyzed without regard for sample thawing was very similar to subset of cyst fluids without multiple freeze/thaws: telomerase activity was significantly higher in the IPMN HGD/invasive cancer cases compared to IPMN cases with IGD, cases with LGD, and cases with SCN, and diagnostic accuracy was only slightly less (AUC 0.83 for IPMN HGD/cancer vs. Figure S11) .
IPMN IGD/LGD) (Supplementary
Among the discovery set cases, the diagnostic accuracy of telomerase activity was not increased significantly by combining this measurement with clinical parameters that predict neoplastic progression of pancreatic cysts (Supplementary Table S4 ).
We also determined if there was evidence for inhibitors of telomerase activity 
cell line extracts were mixed 1:1 with cyst fluid. Minimal reductions in telomerase activity were found when cell line extracts were mixed with greater amounts of cyst fluid, not sufficient to explain the lack of detectable telomerase activity in these samples (Supplementary Figure S12) . Telomerase activity in SCN samples was minimal (median 7 copies/μL) and was not associated with differences in sample freeze/thaws). Since some SCN cyst fluid samples are bloody and since there is modest levels of telomerase activity in inflammatory cells, we also investigated if the bloody cyst fluid samples from SCN cases had higher telomerase measurements. We did find that SCN cyst fluid samples with a bloody appearance had slightly higher levels of telomerase activity than those with a serosanguinous or clear appearance (Supplementary Figure S13) .
To evaluate the diagnostic accuracy of cyst fluid telomerase activity measurements in relation to the pre-operative imaging evaluation of patients, we classified the study population by their clinical features into those with "high-risk stigmata", "worrisome features" and "low-risk" as defined by the revised Sendai criteria (3). (Some patients in this study underwent pancreatic resection before these criteria were developed). Among the 84 discovery set cases, 11 (57.9%) of 19 cases with "high-risk stigmata" and 13 (26.0%) of 50 cases with "worrisome features" had invasive cancer or HGD (Supplementary Figure S14) . Among the 50 discovery set cases with "worrisome features", telomerase measurements had a diagnostic sensitivity for distinguishing those with invasive cancer or HGD from those with lower grades of dysplasia of 92.3% (cut off: 730 copies/μL) and an AUC of 0.927 (Supplementary Table   S5 ). Among the 58 discovery set IPMN cases, 31 had worrisome features and in this group telomerase activity had similarly high diagnostic performance (AUC of 0.876) for distinguishing those with invasive cancer or HGD from those with lower grades of dysplasia (using the cut-off level of 730 copies/μL).
We then analyzed the discovery and validation sets of patients whose samples had not undergone prior thawing in a combined analysis (Figure 2 ), compared these results to other clinical parameters (Table 2) , performed multivariate analysis on this combined set (Table 3) , and examined telomerase activity diagnostic performance according to the preoperative risk classification (Table 4) . Using the 730 copies/μL cyst fluid cut off value, determined by the discovery set results, the diagnostic performance for predicting the presence of high-grade dysplasia/invasive cancer was somewhat higher when all 119 cases were considered (AUC, 0.893; sensitivity, 74.2%; specificity, 93.2%, true-positives 23, false-positives 6, false-negatives 8, true-negatives 82; Figure   2D , Table 2 ) than among the 74 cases with IPMN (AUC, 0.849; sensitivity, 74.2%; specificity, 86.1%, true-positives 23, false-positives 6, false-negatives 8, true-negatives, 37; Figure 2E , Table 2 ). Table 3 shows that the level of telomerase activity as a predictor of malignancy (invasive cancer/HGD) was independent of other factors associated with malignancy by multivariate analysis (which in this series were factors associated with having an IPMN). Table 4 shows that the higher diagnostic performance in the subgroup of patients whose preoperative evaluation was "worrisome features" was similar in the combined (discovery and validation) set (AUC, 0.900; sensitivity, 73.7; specificity, 90.6%; accuracy, 86.1%) as it was in the discovery set (AUC, 0.927; Supplementary We also performed telomerase activity analysis on pancreatic samples obtained by EUS-FNA pre-operatively from 36 cases who underwent subsequent pancreatic resection. A summary of the endoscopic findings, cyst fluid analyses, and pathological diagnoses for these cases are provided in Supplementary Table S6 . In these samples, the telomerase activity levels correlated well with those found in the surgical cyst fluid samples (Supplementary Figure S15) .
DISCUSSION
In the present study, we demonstrate that measurement of telomerase activity in pancreatic cyst fluid samples using dd-TRAP adds diagnostic utility for predicting also be valuable to know if cyst fluid markers can help evaluate the risk of future neoplastic progression of pancreatic cysts that do not currently meet indications for surgical resection or in patients whose pancreatic cysts do meet criteria for surgical resection but elect to undergo surveillance. The diagnostic utility of telomerase activity might also be strengthened by combining the results of cyst fluid analysis obtained at multiple time points during patient surveillance.
In conclusion, quantification of pancreatic cyst fluid telomerase activity using dd-TRAP can accurately predict the presence or absence of invasive cancer/ high-grade dysplasia.
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